The Relationship Between Long-term, Low-dose Macrolide Therapy and Acute Exacerbation in Idiopathic Bronchiectasis Classified by High-resolution Computed Tomography
Abstract Background: High-resolution computed tomography (HRCT) and long-term, low-dose macrolide therapy has been established as a diagnostic method and treatment for bronchiectasis. HRCT correlates with clinical symptoms, respiratory function and quality of life in bronchiectasis. However, whether it will lead to reduction of macrolide therapy effects is unknown. We investigated the relationship between the efficacy of macrolide therapy and severity assessment performed by HRCT in idiopathic bronchiectasis.Methods: Ninety-nine patients with idiopathic bronchiectasis were selected. Acute exacerbation (AE) incidence was set as a comparison factor for the treatment effect. First, patients were divided into the severe and non-severe group based on HRCT. The severe group was defined to have abnormal findings in three or more lobes and in both lungs and the non-severe group as having two or fewer lobes or one side of the lung. Next, each group was divided into subgroups with and without macrolide therapy. Finally, the relationship between macrolide therapy and the AE incidence in each subgroup was compared.Results: Among the 99 idiopathic patients, 50 and 49 were included in the non-severe and severe groups, respectively. In the non-severe group, the subgroup with macrolide therapy had significantly less AE than the subgroup without macrolide (odds ratio [OR] = 0.10, P < 0.036). No significant difference was found in the severe group (OR = 0.70, P = 0.57).Conclusions: HRCT may be useful in predicting the effect of long-term, low-dose macrolide therapy for idiopathic bronchiectasis.